Download PDF
Semin Thromb Hemost 2012; 38(05): 524-529
DOI: 10.1055/s-0032-1306434
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Venous and Arterial Thrombosis Associated with HIV Infection

Francesco Dentali
1   Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
,
Eleonora Nicolini
1   Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
,
Walter Ageno
1   Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
07 March 2012 (online)

    Permissions and Reprints

Abstract

The advent of highly active antiretroviral therapy (HAART) and the appropriate use of prophylactic strategies to prevent opportunistic infections have drastically decreased human immunodeficiency virus (HIV) infection-related mortality. However, there is growing evidence that metabolic abnormalities associated with HIV infection and with its treatment may lead to an increased risk of cardiovascular (CV) events. Several studies showed an increased risk of symptomatic and subclinical CV events in these patients. On the other hand, the association with venous thromboembolic events is less compelling. This increased risk is possibly explained by the coexistence in this population of different risk factors determined by the HIV infection per se, by the higher prevalence of traditional CV risk factors such as obesity, smoking, hypertension, hyperlipidemia, and glucose intolerance, as compared with the general population, and by the effects of HAART. Thus, systematic identification and aggressive treatment of traditional risk factors seem to be necessary to prevent the development of cardiovascular disease in this population.

Keywords

human immunodeficiency virus - acquired immunodeficiency syndrome - venous thrombosis - arterial thrombosis
 

  • References

  • 1 Campsmith ML, Rhodes P, Hall HI , et al. HIV prevalence estimates—United States, 2006. MMWR 2008; 57: 1073-1076
    PubMedGoogle Scholar
  • 2 Joint United Nations Programme on HIV/AIDS. Executive summary: 2008 report on the global AIDS epidemic. Available at: http://www.unaids.org/en . Accessed March 10, 2009
    PubMedGoogle Scholar
  • 3 Palella Jr FJ, Baker RK, Moorman AC , et al ; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43 (1) 27-34
    CrossrefPubMedGoogle Scholar
  • 4 Crum NF, Riffenburgh RH, Wegner S , et al; Triservice AIDS Clinical Consortium. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41 (2) 194-200
    CrossrefPubMedGoogle Scholar
  • 5 Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352 (1) 48-62
    CrossrefPubMedGoogle Scholar
  • 6 Ross AC, Rizk N, O'Riordan MA , et al. Relationship between infiammatory markers, endothelial activation markers and carotid intima-media thickness in HIV-infected patients reciving antiretroviral therapy. Clin Infect Dis 2009; 49: 1119-1127
    CrossrefPubMedGoogle Scholar
  • 7 Vigouroux C, Maachi M, Nguyên TH , et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003; 17 (10) 1503-1511
    CrossrefPubMedGoogle Scholar
  • 8 Ho JE, Hsue PY. Cardiovascular manifestations of HIV infection. Heart 2009; 95 (14) 1193-1202
    CrossrefPubMedGoogle Scholar
  • 9 Hsue PY, Hunt PW, Schnell A , et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23 (9) 1059-1067
    CrossrefPubMedGoogle Scholar
  • 10 de Larrañaga GF, Petroni A, Deluchi G, Alonso BS, Benetucci JA. Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrinolysis 2003; 14 (1) 15-18
    CrossrefPubMedGoogle Scholar
  • 11 Klein SK, Slim EJ, de Kruif MD , et al. Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med 2005; 63 (4) 129-136
    PubMedGoogle Scholar
  • 12 Kaplan RC, Kingsley LA, Sharrett AR , et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007; 45 (8) 1074-1081
    CrossrefPubMedGoogle Scholar
  • 13 Savès M, Chêne G, Ducimetière P , et al; French WHO MONICA Project and the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population.
    PubMedGoogle Scholar
  • 14 Gritz ER, Vidrine DJ, Lazev AB, Amick III BC, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res 2004; 6 (1) 71-77
    CrossrefPubMedGoogle Scholar
  • 15 Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353 (9170) 2093-2099
    CrossrefPubMedGoogle Scholar
  • 16 Brown TT, Cole SR, Li X , et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165 (10) 1179-1184
    CrossrefPubMedGoogle Scholar
  • 17 Grundy SM, Cleeman JI, Daniels SR , et al; American Heart Association ; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112 (17) 2735-2752
    CrossrefPubMedGoogle Scholar
  • 18 Tebas P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr 2008; 49 (Suppl 2) S86-S92
    CrossrefPubMedGoogle Scholar
  • 19 Umeh OC, Currier JS. Lipids, metabolic syndrome and risk factors for future cardiovascular disease among HIV-infected patients. Current HIV/AIDS Rep 2005; 2: 132-139
    PubMedGoogle Scholar
  • 20 Florescu D, Kotler DP. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther 2007; 12 (2) 149-162
    PubMedGoogle Scholar
  • 21 Périard D, Telenti A, Sudre P , et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100 (7) 700-705
    CrossrefPubMedGoogle Scholar
  • 22 Gatell J, Squires K, Piliero P , et al. Atazanavir (BMS-232632): absence of serum lipid changes after 48 weeks of treatment in treatment-naïve HIV positive subjects. Antivir Ther 2000; 6 (Suppl 4) 49S
    PubMedGoogle Scholar
  • 23 Grinspoon SK, Grunfeld C, Kotler DP , et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008; 118 (2) 198-210
    CrossrefPubMedGoogle Scholar
  • 24 Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005; 118 (Suppl 2) 23S-28S
    CrossrefPubMedGoogle Scholar
  • 25 El-Sadr WM, Lundgren JD, Neaton JD , et al; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355 (22) 2283-2296
    CrossrefPubMedGoogle Scholar
  • 26 Hsue PY, Lo JC, Franklin A , et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109: 1603-1608
    CrossrefPubMedGoogle Scholar
  • 27 van Vonderen MG, Smulders YM, Stehouwer CD , et al. Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Defic Syndr 2009; 50 (2) 153-161
    CrossrefPubMedGoogle Scholar
  • 28 Maggi P, Serio G, Epifani G , et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14: 123-128
    CrossrefPubMedGoogle Scholar
  • 29 Currier JS, Kendall MA, Zackin R , et al; AACTG 5078 Study Team. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 19 (9) 927-933
    CrossrefPubMedGoogle Scholar
  • 30 Depairon M, Chessex S, Sudre P , et al; Swiss HIV Cohort Study. Premature atherosclerosis in HIV-infected individuals—focus on protease inhibitor therapy. AIDS 2001; 15 (3) 329-334
    CrossrefPubMedGoogle Scholar
  • 31 Seminari E, Pan A, Voltini G , et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002; 162 (2) 433-438
    CrossrefPubMedGoogle Scholar
  • 32 Hulten E, Mitchell J, Scally J, Gibbs B, Villines TC. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart 2009; 95 (22) 1826-1835
    CrossrefPubMedGoogle Scholar
  • 33 Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348 (8) 702-710
    CrossrefPubMedGoogle Scholar
  • 34 Friis-Møller N, Weber R, Reiss P , et al; DAD study group. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17 (8) 1179-1193
    CrossrefPubMedGoogle Scholar
  • 35 Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512
    CrossrefPubMedGoogle Scholar
  • 36 Currier JS, Taylor A, Boyd F , et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33 (4) 506-512
    CrossrefPubMedGoogle Scholar
  • 37 Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 2010; 121 (5) 651-658
    CrossrefPubMedGoogle Scholar
  • 38 Becker DM, Saunders TJ, Wispelwey B, Schain DC. Case report: venous thromboembolism in AIDS. Am J Med Sci 1992; 303 (6) 395-397
    CrossrefPubMedGoogle Scholar
  • 39 Copur AS, Smith PR, Gomez V, Bergman M, Homel P. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDS 2002; 16 (5) 205-209
    CrossrefPubMedGoogle Scholar
  • 40 Micieli E, Dentali F, Giola M, Grossi P, Venco A, Ageno W. Venous and arterial thrombosis in patients with HIV infection. Blood Coagul Fibrinolysis 2007; 18 (3) 259-263
    CrossrefPubMedGoogle Scholar
  • 41 Laing RBS, Brettle RP, Leen CLS. Venous thrombosis in HIV infection. Int J STD AIDS 1996; 7 (2) 82-85
    CrossrefPubMedGoogle Scholar
  • 42 Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001; 15 (6) 311-320
    CrossrefPubMedGoogle Scholar
  • 43 Lijfering WM, Ten Kate MK, Sprenger HG, van der Meer J. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy. J Thromb Haemost 2006; 4 (9) 1928-1930
    CrossrefPubMedGoogle Scholar
  • 44 Sullivan PS, Dworkin MS, Jones JL, Hooper WC. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000; 14 (3) 321-324
    CrossrefPubMedGoogle Scholar
  • 45 Fultz SL, McGinnis KA, Skanderson M, Ragni MV, Justice AC. Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med 2004; 116 (6) 420-423
    CrossrefPubMedGoogle Scholar
  • 46 Matta F, Yaekoub AY, Stein PD. Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci 2008; 336 (5) 402-406
    CrossrefPubMedGoogle Scholar
  • 47 Malek J, Rogers R, Kufera J, Hirshon JM. Venous thromboembolic disease in the HIV-infected patient. Am J Emerg Med 2011; 29 (3) 278-282
    CrossrefPubMedGoogle Scholar
  • 48 Dubé MP, Stein JH, Aberg JA , et al; Adult AIDS Clinical Trials Group Cardiovascular Subcommittee ; HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37 (5) 613-627
    CrossrefPubMedGoogle Scholar
  • 49 Lundgren JD, Battegay M, Behrens G , et al; EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9 (2) 72-81
    CrossrefPubMedGoogle Scholar
  • 50 Mancia G, De Backer G, Dominiczak A , et al; The task force for the management of arterial hypertension of the European Society of Hypertension ; The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536
    CrossrefPubMedGoogle Scholar
  • 51 Squizzato A, Galli M, Romualdi E , et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J 2010; 31 (10) 1248-1256
    CrossrefPubMedGoogle Scholar